

Special Issue

New Approaches in Vaccine Development for the Control of Vectors and Vector-Borne Diseases

Message from the Guest Editors

Vaccination is an environmentally friendly alternative for the control of emerging vector-borne and infectious diseases. One of the main limitations in the development of effective vaccines for the prevention and control of vector infestation and pathogen transmission is the identification and design of effective protective antigens. Therefore, new challenges such as host immunity, pathogen and environmental factors, vaccine efficacy and safety need to be addressed. This Special Issue aims to include the latest approaches that are being used for the identification and characterization of new vaccine antigen candidates. Potential topics include mosquitoes, ticks, mites, sandflies, malaria, Lyme diseases, anaplasmosis, Crimean–Congo virus, and flaviviruses. Topics related to vector vaccine development, vaccination and vaccine safety are also included. If you need a voucher or waiver, please contact .

Guest Editors

Dr. Marinela Contreras

SaBio, Instituto de Investigación en Recursos Cinegéticos IREC-CSIC-UCLM-JCCM, Ciudad Real, Spain

Dr. Sara Artigas Jerónimo

SaBio, Instituto de Investigación en Recursos Cinegéticos IREC-CSIC-UCLM-JCCM, Ciudad Real, Spain

Deadline for manuscript submissions

closed (30 September 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/124727

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).